Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diabetes and cardiovascular mortality: the impact of sex.
Norhammar A. Norhammar A. Lancet Diabetes Endocrinol. 2018 Jul;6(7):517-519. doi: 10.1016/S2213-8587(18)30111-6. Epub 2018 May 8. Lancet Diabetes Endocrinol. 2018. PMID: 29752193 Free article. No abstract available.
Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
Ritsinger V, Malmberg K, Mårtensson A, Rydén L, Wedel H, Norhammar A. Ritsinger V, et al. Among authors: norhammar a. Lancet Diabetes Endocrinol. 2014 Aug;2(8):627-33. doi: 10.1016/S2213-8587(14)70088-9. Epub 2014 May 13. Lancet Diabetes Endocrinol. 2014. PMID: 24831989 Clinical Trial.
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Nyström T, et al. Among authors: norhammar a. Diabetes Res Clin Pract. 2017 Jan;123:199-208. doi: 10.1016/j.diabres.2016.12.004. Epub 2016 Dec 19. Diabetes Res Clin Pract. 2017. PMID: 28056431 Free article.
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Nyström T, et al. Among authors: norhammar a. Diabetes Obes Metab. 2017 Jun;19(6):831-841. doi: 10.1111/dom.12889. Epub 2017 Mar 16. Diabetes Obes Metab. 2017. PMID: 28116795 Free PMC article.
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI. Persson F, et al. Among authors: norhammar a. Diabetes Obes Metab. 2018 Feb;20(2):344-351. doi: 10.1111/dom.13077. Epub 2017 Sep 8. Diabetes Obes Metab. 2018. PMID: 28771923 Free PMC article.
130 results